Modern Dose-finding Designs For Cancer Phase I Trials: Drug Combinations And Molecularly Targeted A

Thảo luận trong 'Học tập' bởi eb2025, 23/5/2024.

  1. eb2025

    eb2025 Thành viên kỳ cựu

    Tham gia:
    20/5/2024
    Bài viết:
    6,001
    Đã được thích:
    0
    Điểm thành tích:
    86
    Click Here to Download: https://ouo.io/SRrqu5c
    [​IMG]
    Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents
    By: Akihiro Hirakawa; Hiroyuki Sato; Takashi Daimon; Shigeyuki Matsui
    Publisher:
    Springer
    Print ISBN: 9784431555728, 4431555722
    eText ISBN: 9784431555735, 4431555730
    Copyright year: 2018
    Format: EPUB
    Available from $ 54.99 USD
    SKU 9784431555735
    This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.
     

    Xem thêm các chủ đề tạo bởi eb2025
    Đang tải...


Chia sẻ trang này